Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Real-life GH dosing patterns in children with GHD, TS or born SGA: a report from the NordiNet® International Outcome Study

O. Blankenstein, M. Snajderova, J. Blair, E. Pournara, BT. Pedersen, IO. Petit,

. 2017 ; 177 (2) : 145-155. [pub] 20170518

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu časopisecké články, multicentrická studie

Perzistentní odkaz   https://www.medvik.cz/link/bmc17030801

OBJECTIVE: To describe real-life dosing patterns in children with growth hormone deficiency (GHD), born small for gestational age (SGA) or with Turner syndrome (TS) receiving growth hormone (GH) and enrolled in the NordiNet International Outcome Study (IOS; Nbib960128) between 2006 and 2016. DESIGN: This non-interventional, multicentre study included paediatric patients diagnosed with GHD (isolated (IGHD) or multiple pituitary hormone deficiency (MPHD)), born SGA or with TS and treated according to everyday clinical practice from the Czech Republic (IGHD/MPHD/SGA/TS: n = 425/61/316/119), France (n = 1404/188/970/206), Germany (n = 2603/351/1387/411) and the UK (n = 259/60/87/35). METHODS: GH dosing was compared descriptively across countries and indications. Proportions of patients by GH dose group (low/medium/high) or GH dose change (decrease/increase/no change) during years 1 and 2 were also evaluated across countries and indications. RESULTS: In the Czech Republic, GH dosing was generally within recommended levels. In France, average GH doses were higher for patients with IGHD, MPHD and SGA than in other countries. GH doses in TS tended to be at the lower end of the recommended label range, especially in Germany and the UK; the majority of patients were in the low-dose group. A significant inverse association between baseline height standard deviation score and GH dose was shown (P < 0.05); shorter patients received higher doses. Changes in GH dose, particularly increases, were more common in the second (40%) than in the first year (25%). CONCLUSIONS: GH dosing varies considerably across countries and indications. In particular, almost half of girls with TS received GH doses below practice guidelines and label recommendations.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc17030801
003      
CZ-PrNML
005      
20171102103348.0
007      
ta
008      
171025s2017 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1530/EJE-16-1055 $2 doi
035    __
$a (PubMed)28522645
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Blankenstein, Oliver $u Center for Chronic Sick ChildrenInstitute for Experimental Paediatric Endocrinology, Charité - Universitätsmedizin Berlin, Berlin, Germany oliver.blankenstein@charite.de.
245    10
$a Real-life GH dosing patterns in children with GHD, TS or born SGA: a report from the NordiNet® International Outcome Study / $c O. Blankenstein, M. Snajderova, J. Blair, E. Pournara, BT. Pedersen, IO. Petit,
520    9_
$a OBJECTIVE: To describe real-life dosing patterns in children with growth hormone deficiency (GHD), born small for gestational age (SGA) or with Turner syndrome (TS) receiving growth hormone (GH) and enrolled in the NordiNet International Outcome Study (IOS; Nbib960128) between 2006 and 2016. DESIGN: This non-interventional, multicentre study included paediatric patients diagnosed with GHD (isolated (IGHD) or multiple pituitary hormone deficiency (MPHD)), born SGA or with TS and treated according to everyday clinical practice from the Czech Republic (IGHD/MPHD/SGA/TS: n = 425/61/316/119), France (n = 1404/188/970/206), Germany (n = 2603/351/1387/411) and the UK (n = 259/60/87/35). METHODS: GH dosing was compared descriptively across countries and indications. Proportions of patients by GH dose group (low/medium/high) or GH dose change (decrease/increase/no change) during years 1 and 2 were also evaluated across countries and indications. RESULTS: In the Czech Republic, GH dosing was generally within recommended levels. In France, average GH doses were higher for patients with IGHD, MPHD and SGA than in other countries. GH doses in TS tended to be at the lower end of the recommended label range, especially in Germany and the UK; the majority of patients were in the low-dose group. A significant inverse association between baseline height standard deviation score and GH dose was shown (P < 0.05); shorter patients received higher doses. Changes in GH dose, particularly increases, were more common in the second (40%) than in the first year (25%). CONCLUSIONS: GH dosing varies considerably across countries and indications. In particular, almost half of girls with TS received GH doses below practice guidelines and label recommendations.
650    _2
$a mladiství $7 D000293
650    _2
$a dítě $7 D002648
650    _2
$a předškolní dítě $7 D002675
650    _2
$a průřezové studie $7 D003430
650    _2
$a Česká republika $x epidemiologie $7 D018153
650    _2
$a vztah mezi dávkou a účinkem léčiva $7 D004305
650    _2
$a hypofyzární nanismus $x diagnóza $x farmakoterapie $x epidemiologie $7 D004393
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a následné studie $7 D005500
650    _2
$a Francie $x epidemiologie $7 D005602
650    _2
$a Německo $x epidemiologie $7 D005858
650    _2
$a poruchy růstu $x diagnóza $x farmakoterapie $x epidemiologie $7 D006130
650    _2
$a lidský růstový hormon $x aplikace a dávkování $7 D019382
650    _2
$a lidé $7 D006801
650    12
$a hypotrofický novorozenec $7 D007236
650    12
$a internacionalita $7 D038622
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a prospektivní studie $7 D011446
650    12
$a výzkumná zpráva $7 D058028
650    _2
$a výsledek terapie $7 D016896
650    _2
$a Turnerův syndrom $x diagnóza $x farmakoterapie $x epidemiologie $7 D014424
650    _2
$a Spojené království $x epidemiologie $7 D006113
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
700    1_
$a Snajderova, Marta $u 2nd Faculty of MedicineCharles University and University Hospital Motol, Prague, Czech Republic.
700    1_
$a Blair, Jo $u Alder Hey Children's NHS Foundation TrustLiverpool, UK.
700    1_
$a Pournara, Effie $u Novo Nordisk Health Care AGZurich, Switzerland.
700    1_
$a Pedersen, Birgitte Tønnes $u EpidemiologyNovo Nordisk A/S, Søborg, Denmark.
700    1_
$a Petit, Isabelle Oliver $u Department of Paediatric EndocrinologyHôpital des Enfants, Toulouse, France.
773    0_
$w MED00009634 $t European journal of endocrinology $x 1479-683X $g Roč. 177, č. 2 (2017), s. 145-155
856    41
$u https://pubmed.ncbi.nlm.nih.gov/28522645 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20171025 $b ABA008
991    __
$a 20171102103441 $b ABA008
999    __
$a ok $b bmc $g 1254394 $s 991828
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2017 $b 177 $c 2 $d 145-155 $e 20170518 $i 1479-683X $m European journal of endocrinology $n Eur J Endocrinol $x MED00009634
LZP    __
$a Pubmed-20171025

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace